About X-Body Biosciences
X-Body Biosciences is a company based in Waltham (United States) founded in 2008 by Hans Bishop was acquired by Juno Therapeutics in June 2015.. X-Body Biosciences has raised $7.8 million across 3 funding rounds from investors including Juno Therapeutics. X-Body Biosciences operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Waltham, United States
- Founders Hans Bishop
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$7.8 M (USD)
in 3 rounds
-
Latest Funding Round
$2.66 M (USD), Series A
Apr 08, 2015
- Investors
-
Employee Count
Employee Count
-
Acquired by
Juno Therapeutics
(Jun 02, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of X-Body Biosciences
X-Body Biosciences has successfully raised a total of $7.8M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $2.66 million completed in April 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $2.7M
-
First Round
First Round
(01 Jan 2009)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2015 | Amount | Series A - X-Body Biosciences | Valuation |
investors |
|
| Jan, 2012 | Amount | Series A - X-Body Biosciences | Valuation |
investors |
|
| Jan, 2009 | Amount | Seed - X-Body Biosciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in X-Body Biosciences
X-Body Biosciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Juno Therapeutics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by X-Body Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - X-Body Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
X-Body Biosciences Comparisons
Competitors of X-Body Biosciences
X-Body Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on X-Body Biosciences
Frequently Asked Questions about X-Body Biosciences
When was X-Body Biosciences founded?
X-Body Biosciences was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Where is X-Body Biosciences located?
X-Body Biosciences is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Who is the current CEO of X-Body Biosciences?
Hans Bishop is the current CEO of X-Body Biosciences. They have also founded this company.
Is X-Body Biosciences a funded company?
X-Body Biosciences is a funded company, having raised a total of $7.8M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Jan 01, 2009.
What does X-Body Biosciences do?
X-Body Biosciences was founded in 2008 in Waltham, United States, within the biotechnology sector. Monoclonal antibody therapeutics are discovered and developed against targets in oncology and ophthalmology. A DNA-tagged human antibody library is employed for antibody discovery, complemented by a high-throughput label-free screening system to identify high-affinity candidates. Operations have been conducted as a subsidiary of Juno Therapeutics since June 1, 2015.
Who are the top competitors of X-Body Biosciences?
X-Body Biosciences's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Who are X-Body Biosciences's investors?
X-Body Biosciences has 1 investor. Key investors include Juno Therapeutics.